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techniques for palliating primary esophageal cancer
Peter D. Siersema, MD, PhD, FASGE, Frank P. Vleggaar, MD, PhDDepartment of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands.Of all nonstent modalities available for palliating esophageal cancer, brachytherapy with or without
external beam radiation therapy is the best modality, providing a survival benefit with a better quality
of life in the long-term compared with stent placement. Both stent placement and brachytherapy provide
comparable palliation to endoscopic chemical ablative therapy but are preferable because of the reduced
requirement for reintervention. Other available modalities, such as laser therapy, photodynamic ther-
apy, or chemical ablation, are not recommended for palliation of dysphagia because of a high incidence
of complications and recurrent dysphagia.
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Open access under the Elsevier OA license. Nutritional supportThe incidence of esophageal cancer has risen markedly
over the past 3 decades in the Western world because of a
marked increase in the incidence of adenocarcinoma.1,2 The
prognosis of esophageal cancer is poor, with a 5-year sur-
vival rate of 10% (United States) and 16% (Europe).3 Sur-
ical resection with or without neoadjuvant chemotherapy
r chemoradiation is currently the primary treatment for
sophageal cancer if the patient is fit enough to undergo
urgery and the tumor is considered resectable without
vidence of distant metastases.4
Because the tumor is often asymptomatic in the early
stages, more than 50% of patients are diagnosed at an
advanced stage, involving locally unresectable disease or
distant metastases. A subgroup of patients includes patients
with locally unresectable tumors (T4N0-1M0-Ia), who are
in a good general condition, or patients who refuse surgery.
For these patients, a definitive treatment schedule of che-
motherapy or chemoradiation may be beneficial.5
Unfortunately, most patients with inoperable disease
have metastases or a poor medical condition. Median sur-
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Open access under the Elsevier OA license. vival of these patients is approximately 5-6 months, and in
most, a palliative treatment is warranted to restore or main-
tain the ability to eat. There is a wide range of palliative
treatment modalities available to relieve dysphagia in pa-
tients with inoperable esophageal cancer (Table 1). These
include mechanical measures, such as dilation, stent place-
ment, and surgery, and antineoplastic methods, such as
radiation therapy (external beam radiation therapy [EBRT],
intraluminal radiotherapy [brachytherapy], or combined),
laser therapy, photodynamic therapy (PDT), chemical abla-
tion using injection of alcohol or chemotherapeutic agents,
and nutritional support.
The optimal treatment for dysphagia caused by advanced
primary esophageal cancer is not established, although con-
tinued progress is ongoing to achieve this goal. Worldwide,
most patients are palliated with stents. In this review, we
will report the efficacy of nonstent, palliative modalities
(Table 1) that are used for the palliation of dysphagia in
patients with primary esophageal cancer.
Nonstent palliative modalities
Dilation
Pros
● Easy to perform
● Cheap, especially when bougies are used
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● Repeat treatment sessions are necessary within 2-4 weeks
● Risk of perforation
Dilation can relieve dysphagia temporarily, but it often
rovides palliation for only a few days and up to 4 weeks.6
It is sometimes used to allow access through the tumor for
different forms of palliative treatments such as stent place-
ment. Dilation is a simple and cheap method, but compli-
cations, including perforation and hemorrhage, occur and
are reported in up to 10% of patients.
Some authors advocate systematically increasing dilation
of a malignant stricture over several sessions; however,
scientific evidence for this is lacking. The most commonly
used dilators are polyvinyl wire-guided bougies, the most
common of which are Savary–Gilliard dilators (Figure 1)
and through-the-scope hydrostatic balloons. There is no
study comparing these dilators in patients with malignant
strictures and demonstrating a benefit of either method.
Because dilation as a sole therapy must be repeated at
frequent (1- to 4-week) intervals, it should only be per-
formed in patients with a very short life span in whom stent
placement may not be considered cost-effective.
Brachytherapy
Pros
● Long-term effectiveness
● Relatively low complication rate
ons
● Up to 15% persistent dysphagia after treatment
● Long-term effectiveness (ie, improvement of dyspha-
gia) in approximately 50% of patients in single-arm
retrospective series
● No short-term (1 month) benefit
In 1980, brachytherapy was introduced as a boost after
BRT for the treatment of esophageal squamous cell car-
Table 1 Palliative treatment modalities for treating
dysphagia from esophageal cancer
Modality
Mechanical methods Antineoplastic methods
Dilation Radiation therapy
Stent placement external beam radiotherapy (EBRT)
Surgery intraluminal radiotherapy
(brachytherapy)
Combined EBRT  brachytherapy
Nd:YAG laser therapy
Photodynamic therapy
Chemical ablation with alcohol or
chemotherapeutic agents
Nutritional support
Nasoenteral feeding tube
Percutaneous endoscopic
gastrostomy (PEG)inoma. Five years later, brachytherapy as a single treat-ent was reported to be effective for the palliation of
ysphagia from inoperable esophageal cancer.7 The most
commonly used radioactive source is iridium (192Ir).
Brachytherapy is increasingly being delivered at a high dose
rate with a dose of 12 Gy or more per hour. This regimen
substantially reduces treatment time compared with previ-
ous schedules and can be performed as an outpatient pro-
cedure. Several studies have used brachytherapy as a single
treatment using a dose of 7.5-20 Gy in 1-3 fractions.8
Dysphagia improvement has been reported in 50% of
patients. The complication rate after single-dose brachyther-
apy is low (20%) and mainly consists of fistula formation,
mild retrosternal pain, and radiation esophagitis. Persistent/
recurrent dysphagia following single-dose brachytherapy is
most commonly caused by tumor persistence (15%), tumor
recurrence (35%), and benign stricture formation (5%).9
Proven effective brachytherapy strategies are 12 Gy
given in 1 fraction, 16 Gy given in 2 fractions, or 21 Gy
given in 3 fractions, although future studies are warranted to
optimize the treatment strategy.8
Neodymium yttrium–aluminum–garnet (Nd:YAG)
laser therapy
Pros
● Low complication rate (only in experienced hands!)
● Preferable for exophytic tumors
ons
● Technically difficult to perform
● Expensive
Figure 1 Increasing sizes (top to down) of Savary–Gilliard
dilators that can be used to dilate a malignant or benign esophageal
stricture. These dilators are usually advanced over a stiff guidewire
(0.038 inch). (Color version of figure is available online at www.
techgiendoscopy.com).
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205Siersema and Vleggaar Alternative Techniques for Palliating Primary EC● Repeated treatment sessions necessary every 4-6 weeks
● Risk of perforation in submucosal tumors, tumors with
extrinsic compression, and angulated tumors
Treatment of obstructing esophageal cancer with the
igh-power Nd:YAG laser is another relatively safe but
ften temporary palliation of dysphagia. Tumors that are
elatively short (6 cm), exophytic, and located in the
id-esophagus are most amenable to laser ablation. Laser
reatment is unsafe for submucosal tumors, tumors causing
xtrinsic compression, and angulated tumors, whereas cir-
umferential tumors are vulnerable to stricture formation. It
s less effective for cancer of the proximal esophagus or
astroesophageal junction.6,10
Dysphagia improvement is significant (ie, 35%-80% of
patients are able to eat solids starting a few days after the
procedure). However, many patients (70%-95%) require
more than 1 treatment session. Therefore, patients are usu-
ally reassessed at 4- to 6-week intervals. Complications
include perforation and to a lesser extent fistula formation,
hemorrhage, and sepsis in 5%-10% of patients. The com-
plication rate increases in nonexperienced hands.10 More-
ver, laser equipment is expensive and the equipment is
sually large.
Photodynamic therapy
Pros
● Technically easier and less operator dependent than
Nd:YAG laser
ons
● Expensive
● Skin photosensitivity for a prolonged period
● Repeated treatment session necessary after 8 weeks
PDT involves the local destruction of tumor tissue using
he light of a specific wavelength activating a previously
dministered photosensitizer, which is retained in malignant
issue. Porphyrin compounds, such as porfimer sodium
Photofrin), have been the most commonly used photosen-
itizers for the palliation of malignant dysphagia. Clinical
xperience with PDT for palliation of malignant dysphagia
s limited to a few centers in western Europe, Canada, and
he United States. One or two treatment sessions are usually
equired for an adequate tumor response. The most frequent
omplication is prolonged skin photosensitivity. Patients
ust avoid direct sunlight for a period of 4 to 6 weeks after
reatment.6,11
Dysphagia improvement is seen in 40%-70% of patients;
however, because of recurrent tumor growth, treatment
must be repeated every 6-8 weeks. Major complications,
including perforation, fistula formation, and (benign) stric-
tures, have been reported in up to 30% of patients. Other
side effects include fever, chest pain, and pleural effusion,
probably secondary to a transient, local inflammation, but
the latter adverse effects are usually mild.11
The costs of PDT are high because of the high costs of a
special laser unit and those of Photofrin.Chemical injection therapy
Pros
● Easy to perform
● Cheap, depending on injection fluid used
ons
● Treatment effect is unpredictable and depends on local
factors, such as tumor characteristics (firm/fibrotic vs
loose) and spreading of injection fluid into the sur-
rounding tissue
● Repeated treatment session necessary at 4- to 6-week
intervals
Chemical injection therapy for the treatment of malignant
ysphagia is an inexpensive alternative requiring no special
quipment. Ethanol or polidocanol in aliquots of 0.5-1 mL
s injected into the tumor, leading to tumor necrosis within
everal days after therapy. Some anecdotal experience has
eported the use of chemotherapeutic agents.6 Exophytic
tumors are most amenable to injection therapy, whereas firm
and fibrotic tumors (after radiotherapy) prove difficult to
inject.
Dysphagia improvement is seen in 80%-90% of patients.
Complications are rare but only a few studies have been
reported, with fistula formation (n 2), perforation (n 1),
and mediastinitis (n  1) as the major ones.6 In general, 2
sessions were necessary to obtain a maximum effect and
retreatment was necessary at 4- to 6-week intervals. The
main disadvantage is that the treatment effect cannot be
predicted, for example, in chemical injection therapy, where
there is a risk of unwanted complications, such as perfora-
tion and fistula formation.6
Nutritional support
Pros
● Escape treatment when other palliative treatments fail
or are technically not possible and survival of patients
is at most 4-6 weeks
ons
● Difficult to decide when to stop nutritional support in
end-stage esophageal cancer
When different palliative therapies fail (stent placement
as no effect) or when other palliative modalities are tech-
ically not possible, nutritional support to maintain ade-
uate calorie intake can be considered. The overall condi-
ion and the prognosis of the patient should be considered
efore nutritional support is offered to a patient. Further-
ore, tumor-induced cachexia may not respond to forced
utritional intake. Placement of a nasoenteral feeding tube is
he easiest and least invasive feeding method. Maintaining
he position of an endoscopically placed nasoenteral feeding
ube beyond the pylorus is often problematic because of
etrograde migration. Fixation of a feeding tube to the small
ntestinal wall with an Endoclip may prevent this (Figure 2).12 For
some patients with a longer life expectancy, placement of a
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PEJ) is the preferred strategy. Only rarely, central venous
alimentation is indicated for maintaining or restoring ade-
quate nutritional status. It can be difficult to decide when to
stop nutritional support in end-stage esophageal cancer pa-
tients, particularly when quality of life (QoL) is no longer
positively affected.6
Placement of a PEG using the classic “pull” method
through a preexisting esophageal stent or in the presence of
a malignancy can be problematic. In these cases, PEG
placement without endoscopy using a direct percutaneous
catheter insertion technique (“push” method) is indicated.
Comparative studies
Based on the results of various treatment modalities used
for the palliation of dysphagia in esophageal cancer, it is
difficult to decide what the most optimal treatment is. A
physician’s experience with a particular palliative method
and patient characteristics, such as expected survival, will
likely influence treatment choice. In patients with an ex-
pected survival 2 weeks, an easy-to-apply treatment, such
as dilation, is worthwhile to consider because the relatively
high risk of recurrent stenosis is less important in this group.
By contrast, in patients with an expected survival 3
onths, a prolonged treatment effect, such as that caused by
adiation therapy, is important to consider.
In the following, we will summarize some of the pub-
ished randomized controlled trials (RCTs) related to palli-
tion of malignant dysphagia in which at least 1 nonstent
odality was included for comparison. A summary of all
ublished RCTs can be found in a recently published Co-
Figure 2 Fixation of a nasoenteral feeding tube to the wall of
he duodenum with an Endoclip in an effort to prevent retrograde
igration of the tube. (Color version of figure is available online
t www.techgiendoscopy.com).hrane review.13Stents versus brachytherapy
Two studies randomized 274 patients to Ultraflex stent
(Boston Scientific, Natick, MA) or brachytherapy.14,15 In the
largest of the 2 studies (n  209), 1 dose (12 Gy) of
rachytherapy was delivered,14 whereas in the other study 3
doses (3  7 Gy) in 2-4 weeks were delivered.15 Both
tudies included patients with esophageal adenocarcinoma
nd squamous cell carcinoma.
In the study by Homs et al,14 dysphagia improved more
rapidly after stent placement than after brachytherapy, but
long-term relief of dysphagia was better after brachytherapy
(Figure 3). Stent placement had more complications than
Figure 3 (A) Immediate relief of dysphagia after stent placement.
(B) The effect of brachytherapy (as seen here 5 days after treatment)
on dysphagia relief takes usually 2-4 weeks. (Color version of figure
is available online at www.techgiendoscopy.com).
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207Siersema and Vleggaar Alternative Techniques for Palliating Primary ECbrachytherapy (36/108 [33%] vs 21/101 [21%]; P  0.02),
hich was mainly caused by an increased incidence of late
leeding (14 [13%] vs 5 [5%]; P  0.05). The treatments
id not differ in persistent or recurrent dysphagia or median
urvival. QoL after 3 months was in favor of brachytherapy
ompared with stent placement. Total medical costs were
imilar for stent placement ($10,348) and brachytherapy
$10,247). In the Bergquist et al study,15 QoL was the
primary endpoint, which was reported in detail. The authors
concluded (like Homs et al14) that long-term QoL remained
more stable in patients treated with brachytherapy compared
with those treated with stent placement.
In summary, despite slow improvement, single-dose
brachytherapy gives better long-term relief of dysphagia
and better QoL, with fewer complications than stent place-
ment.
The Dutch group used their results to develop a prog-
nostic model that could help guiding treatment (ie, stent
placement or brachytherapy) in individual patients who had
dysphagia from esophageal cancer.16 A simple score was
eveloped, which included age (increasing age has a worse
rognosis), gender (men have a worse prognosis), tumor
ength (increasing length is associated with a worse prog-
osis), World Health Organization (WHO) performance
core, and presence of metastases (Table 2). A total score
ased on these factors was used to differentiate among
atients with a relatively poor, intermediate, or good prog-
osis. In the intermediate and good prognostic groups,
rachytherapy resulted in better dysphagia-adjusted sur-
ival. Alternatively, in the poor prognosis group, the differ-
nce in dysphagia-adjusted survival was 23 days in favor of
tent placement compared with brachytherapy (77 days vs
4 days). Based on this model, it was recommended that
tents should be used in patients with a calculated life
xpectancy of 3 months and that brachytherapy should be
Table 2 Results of brachytherapy versus stent placement by
prognostic risk group
Prognostic group Brachytherapy Stent P value
Good (score  3.5*)
Median survival (days) 218 189 0.13
Dysphagia-adjusted
survival (days)
138 104 0.17
Intermediate (score 3.5-5*)
Median survival (days) 147 132 0.35
Dysphagia-adjusted
survival (days)
98 68 0.09
Poor (score  5*)
Median survival (days) 75 90 0.47
Dysphagia-adjusted
survival (days)
54 77 0.16
*Score chart for survival with total score of items (a)-(e) deter-
mining total score: (a) gender, female, 0; male, 1; (b) age: 40 years,
1; 50 years, 0.5; 60 years, 0; 70 years, 0.5; 80 years, 1; (c) tumor
length: 10 cm, 2; (d) metastases: 2; and (e) World Health Organiza-e
tion performance score: score 1, 1; score 2, 2; score 3, 3.eserved for patients with a life expectancy 3 months.
tent placement should also be reserved for patients with
ersistent or recurrent tumor after brachytherapy.
Stents versus laser therapy
Two studies randomized 125 patients.17,18 Both studies
sed uncovered Strecker or Ultraflex stents and covered
allstents of similar diameter. In the Dallal et al study18
(n  65), not all patients were treated with Nd:YAG laser
therapy; some patients (n  9) were treated with argon
plasma coagulation instead.18
Stent placement was successful in all patients; whereas
laser therapy was not possible for technical reasons in 7/52
(13.5%) patients (pooled odds ratio [OR] 12.2, 95% confi-
dence interval [CI] 1.40-106.2). Dysphagia improvement
was not different between patients treated with a stent or
laser therapy (pooled analysis was not possible). Twenty-
eight of 73 (38.4%) stented patients and 10/52 (19.2%)
patients treated with laser had complications (pooled OR
2.26, 95% CI 0.96-5.33) such as perforation, fistula, bleed-
ing, bolus obstruction, tumor regrowth, and tumor over-
growth. Perforation and fistula formation were only ob-
served in the laser group and bleeding and migration only in
the stent group. Persistent or recurrent dysphagia occurred
in 18/70 (25.7%) patients with a stent and in 16/52 (30.8%)
patients treated with laser therapy (pooled OR 0.67, 95% CI
0.30-1.54) in favor of stent placement. Twenty-five of 73
(34.2%) patients required a reintervention in the stent group
and 31/52 (59.6%) patients in the laser group (pooled OR
0.27, 95% CI 0.12–0.60 in favor of stent placement). This
was caused by the fact that Adam et al17 considered all
ubsequent laser therapies as reinterventions. Repeated laser
reatment is required to provide adequate palliation. Dallal
t al found a significant increase in median survival for laser
herapy (125 days) compared with stent placement (68
ays).18 In that study, QoL at 1 month also indicated that
hysical function, physical health, pain and emotional
ealth, and cancer-specific questionnaires were significantly
orse in patients with a stent compared with those treated
ith laser.
In summary, improvement of dysphagia and compli-
ations and recurrent dysphagia did not differ between
tent placement and laser therapy. However, it is evident
hat some complications are specific for each group.
inally, it is uncertain whether the results regarding
verall survival and QoL (in favor of laser therapy) and
hose regarding technical success and reintervention (in
avor of stent placement) can be extrapolated to routine
linical practice.
Other studies comparing stents with other
modalities
Six RCTs compared stent placement with various
other modalities.19-24 Comparisons included stent versus
sophageal bypass surgery,19 stent versus stent plus laser
v208 Techniques in Gastrointestinal Endoscopy, Vol 12, No 4, October 2010therapy versus laser plus radiotherapy,20 stent versus
PDT,21 stent versus EBRT,22 stent versus stent followed
by chemotherapy or chemoradiation,23 and stent versus
rigid plastic tube placement versus nonstent therapy (in-
cluding EBRT, brachytherapy, thermal ablation therapy,
and ethanol tumor necrosis, which were left to the dis-
cretion of the treating physicians).24
In summary, stent placement is effective and safe and
provides rapid relief in the palliation of dysphagia compared
with other modalities; importantly, it avoids delays in ef-
fectively treating these patients. However, this analysis also
demonstrates that other modalities, including brachytherapy
and EBRT, may provide a survival advantage and possibly
better QoL compared with stent treatment.
Other studies comparing laser therapy with other
modalities
Six RCTs compared laser therapy with radiation therapy
or laser therapy with laser therapy augmented by radiother-
apy.25-30 Comparisons included laser versus brachyther-
apy,25 laser versus laser augmented by EBRT,26 and laser
ersus laser augmented by brachytherapy.27-30
In addition, laser therapy was also compared with other
nonstent modalities (ie, laser vs PDT,31,32 laser vs rigid
plastic tube placement,33-35 and laser vs chemical abla-
tion).36,37
In summary, laser treatment and brachytherapy are com-
parable in palliating dysphagia in patients with primary
esophageal cancer. This analysis provides evidence to sup-
port the augmenting effect of EBRT and brachytherapy to
laser treatment to improve dysphagia-free interval and re-
duce recurrent dysphagia. There is equivocal evidence that
addition of brachytherapy to laser treatment reduces the
need for reintervention. Adding brachytherapy to laser ther-
apy does not improve overall survival and QoL or reduce
complications.
Conclusions
The currently available stent and nonstent modalities
for the palliation of malignant dysphagia are not yet
optimal in achieving fast and sustained dysphagia relief
with minimal morbidity and mortality. Of all methods,
brachytherapy may be the safest modality given the re-
sults on improvement of dysphagia and QoL in the longer
term. This is particularly true for patients with a rela-
tively good prognosis.
In the future, combination treatments will likely be in-
creasingly used, especially in patients with a “good” prog-
nosis. In this regard, a combination of a dysphagia-relieving
treatment (stent or brachytherapy) with a treatment modality
that has an effect on the tumor mass, both local and sys-
temic, such as chemotherapy, EBRT, or, preferably, chemo-
radiation, is most attractive. These new combinations
should be studied in well-designed RCTs that focus on notonly dysphagia relief, complications, QoL, and costs, but
also survival.
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